Mirum Pharmaceuticals, Inc. MIRM Proceeds from exercises of stock options and other stock issuances
Proceeds from exercises of stock options and other stock issuances at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mirum Pharmaceuticals, Inc.'s proceeds from exercises of stock options and other stock issuances.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mirum Pharmaceuticals, Inc.'s proceeds from exercises of stock options and other stock issuances?
- Mirum Pharmaceuticals, Inc. (MIRM) reported proceeds from exercises of stock options and other stock issuances of $10.13M in Q1 2026.
- How has Mirum Pharmaceuticals, Inc.'s proceeds from exercises of stock options and other stock issuances changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s proceeds from exercises of stock options and other stock issuances increased by 59.3% year-over-year, from $6.36M to $10.13M.
- What is the long-term trend for Mirum Pharmaceuticals, Inc.'s proceeds from exercises of stock options and other stock issuances?
- Over 4 years (2021 to 2025), Mirum Pharmaceuticals, Inc.'s proceeds from exercises of stock options and other stock issuances has grown at a 109.1% compound annual growth rate (CAGR), from $2.1M to $40.14M.